⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635054 | 1.00 | — | — | |
| SCHEMBL9720405 | 1.00 | — | — | |
| SCHEMBL1635053 | 1.00 | — | — | |
| SCHEMBL18107343 | 0.85 | — | — | |
| SCHEMBL24649615 | 0.78 | — | — | |
| SCHEMBL13799410 | 0.78 | — | — | |
| SCHEMBL18107318 | 0.78 | — | — | |
| SCHEMBL18107486 | 0.78 | — | — | |
| SCHEMBL20694099 | 0.78 | — | — | |
| SCHEMBL9416085 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570625-B2 | 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2026-03-10 | — | — | US | disclosed |
| US-12479817-B2 | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof | NOVARTIS AG (CH) | 2025-11-25 | — | — | US | disclosed |
| US-20250289802-A1 | 3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-18 | — | — | US | disclosed |
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4501926-A1 | N-SUBSTITUTED QUINOLINONE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Vigonvita Life Sciences Co., Ltd. (CN) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024260325-A1 | SYNTHESIS OF MACROCYCLIC COMPOUND AND MEDICAL USE OF MACROCYCLIC COMPOUND | 英矽智能科技知识产权有限公司 | 2024-12-26 | — | — | WO | disclosed |
| US-20240245670-A1 | DOSING REGIMEN AND PHARMACEUTICAL COMBINATION COMPRISING 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES | NOVARTIS AG (CH) | 2024-07-25 | — | — | US | disclosed |
| US-20240239785-A1 | SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-5-(1-PIPERIDIN-4-YL)ISOINDOLINE-1,3-DIONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. | 2024-07-18 | — | — | US | disclosed |
| CN-113329792-B | Substituted 3- (1-oxo-isoindolin-2-yl) piperidine-2, 6-dione derivatives and uses thereof | 诺华股份有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024092274-A2 | ENDOCYTIC AGENTS | BIOVENTURES, LLC (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20040033959-A1 | Improved bioavailability | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-02-19 | — | — | US | disclosed |
| US-20040029932-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20040023999-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20040010148-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-01-15 | — | — | US | disclosed |
| US-20040010020-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003104195-A1 | 4-(ARYL OR HETEROARYL) -2-BUTYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232823-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003101932-A2 | GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030195228-A1 | Viricide mixtures comprising heterocyclic imines, amines, oils, carriers, solvents and optionally surfactants, having improved bioavailability; enzyme inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003066103-A1 | PHARMACEUTICAL COMPOSITIONS FOR HEPATITIS C VIRAL PROTEASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-08-14 | — | — | WO | disclosed |